Skip to content
value.today

CVRx, Inc.

CVRX
$48 Mmarket cap on Oct 9, 2026-92.2% since Jan 2024
Compare
World rank
#21,410
Revenue
$57 M
For year ending December-2025
Net income
$-53 M
-94.1% margin
SEC filing
Employees
223
As of December 31, 2025
SEC filing

CVRx, Inc. in brief

CVRx, Inc. is a listed company in the Medical Devices industry, based in Minneapolis, Minnesota, USA. Its market value was $48 M on 9 October 2026, which makes it the 21,410th largest listed company in the world and the 3,860th largest in the USA on this site. In the year to December 2025 it had sales of $57 M and a net loss of $53 M. It employs about 223 people and Kevin Hykes is its chief executive. By market, the largest shares of its 2025 sales came from USA (92%) and Germany (8%). Its shares trade under the symbol CVRX (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Barostim is the first medical technology approved by the U.S. Food and Drug Administration that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, which creates an imbalance in the brain’s Autonomic Nervous System resulting in excess neurohormones that drive HF progression. Barostim provides Baroreflex Activation Therapy, which links the cardiovascular system to the ANS. This therapy complements the pharmaceutical neurohormonal blockade, or Guideline Directed Medical Therapy, by increasing the signaling of the baroreceptors, thereby, reducing symptoms of HF. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in HF patients in the U.S. We estimate our total market opportunity using both prevalence and incidence epidemiologic models in which prevalence reflects the total number of individuals indicated for therapy at a given time, while incidence captures the annual occurrence of new cases meeting the indication. Based on these distinct models, we estimate that our prevalence-based market opportunity for HFrEF is $10.5 billion in the U.S. Using an incidence-based model, we estimate an annual market opportunity of $2.4 billion in the U.S.

From the company's annual report filed with the US SEC: read the report

CVRx, Inc. timeline

3 events, 2003–2025
  1. 2003
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 1 July 2021; shares registered for exchange trading on 25 June 2021.
  5. 2025
  6. 💰
    Record revenue of $57 million
    FY2025, the highest of the 6 years on record.

Events of CVRx, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$166 M$333 M$499 M$665 M2023202420252026

World rank over time

▼ down 2,873 places since 2022
2022-01-07: #18659#18,65920222022-12-25: #14874#14,87420222023-07-30: #14670#14,67020232024-01-05: #11332#11,33220242026-03-08: #8866#8,86620262026-08-01: #17986#17,98620262026-10-09: #21532#21,5322026

Rank in USA: #3,779 (Jan 2022) · #3,057 (Dec 2022) · #2,978 (Jul 2023) · #2,375 (Jan 2024) · #1,671 (Mar 2026) · #3,531 (Aug 2026) · #3,859 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.8×
Price / book
1.2×
Free cash flow yield
-85.2%
Net margin (TTM)
-88.3%
Operating margin
-90.5%
Return on equity
-135.4%
Liabilities / assets
62.5%
Net debt
$-26M
Revenue growth
+10.5%
R&D / revenue
19.6%
Revenue per employee
$254 K
Profit per employee
$-239 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $6M, net income $-14M$6MFY20Fiscal year ending Dec 2021: revenue $13M, net income $-43M$13MFY21Fiscal year ending Dec 2022: revenue $22M, net income $-41M$22MFY22Fiscal year ending Dec 2023: revenue $39M, net income $-41M$39MFY23Fiscal year ending Dec 2024: revenue $51M, net income $-60M$51MFY24Fiscal year ending Dec 2025: revenue $57M, net income $-53M$57MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$57M+10.5%$-51M$-53M-94.1%
Dec 2024$51M+30.5%$-59M$-60M-116.9%
Dec 2023$39M+74.9%$-43M$-41M-104.8%
Dec 2022$22M+72.3%$-43M$-41M-184.4%
Dec 2021$13M+115.5%$-26M$-43M-330.4%
Dec 2020$6M—$-12M$-14M-233.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-40M$1M$-41M$-2.04—
Dec 2024$-39M$1M$-41M$-2.65—
Dec 2023$-39M$1M$-40M$-1.99—
Dec 2022$-43M$1M$-43M$-2.02—
Dec 2021$-28M$1M$-29M$-4.16—
Dec 2020$-16M$0M$-16M$-37.01—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$60M
Net income, trailing 12 months
$-53M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $15M, net income $-11M$15MDec ’24Three months to Mar 2025: revenue $12M, net income $-14M$12MMar ’25Three months to Jun 2025: revenue $14M, net income $-15M$14MJun ’25Three months to Sep 2025: revenue $15M, net income $-13M$15MSep ’25Three months to Dec 2025 (from the annual report): revenue $16M, net income $-12M$16MDec ’25Three months to Mar 2026: revenue $15M, net income $-13M$15MMar ’26Three months to Jun 2026: revenue $16M, net income $-14M$16MJun ’26Three months to Sep 2026: revenue $14M, net income $-14M$14MSep ’26

Latest quarter to Sep 2026: revenue $14M (-5.9% on a year earlier), net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of CVRx, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$57 M
Operating income
$-51 M
Net income
$-53 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$105 M
Total liabilities
$65 M
Total equity
$39 M

As of December-2025

Top 87 institutional investors in CVRx, Inc.#

As of Sep 30, 2026
87 institutions held 15.5 M shares (about 54.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 40.6%. Filings read through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in CVRx, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Johnson & Johnson4,024,8610 (0.00%)14.13%$7 MOct 26, 2026
2NEA Management Company, LLC1,954,4400 (0.00%)6.86%$3 MNov 16, 2026
3BlackRock, Inc.1,286,784+41,325 (+3.32%)4.52%$2 MNov 13, 2026
4GSK plc1,007,5830 (0.00%)3.54%$2 MNov 5, 2026
5Vanguard Capital Management LLC902,426-8,150 (-0.90%)3.17%$2 MNov 13, 2026
6Citadel Advisors LLC652,362+573,349 (+725.64%)2.29%$1 MNov 16, 2026
7Royal Bank Of Canada516,789-716,423 (-58.09%)1.81%$1 MNov 16, 2026
8Renaissance Technologies LLC435,400+205,400 (+89.30%)1.53%$1 MNov 12, 2026
9Geode Capital Management, LLC423,090-17,696 (-4.01%)1.49%$1 MNov 6, 2026
10Goldman Sachs Group Inc372,175+222,666 (+148.93%)1.31%$1 MNov 16, 2026
11State Street Corp346,524-19,828 (-5.41%)1.22%$1 MNov 12, 2026
12Morgan Stanley273,512+128,535 (+88.66%)0.96%$0 MNov 13, 2026
13First Eagle Investment Management, LLC220,758New0.78%$0 MNov 10, 2026
14Tudor Investment Corp Et Al208,058+2,374 (+1.15%)0.73%$0 MNov 16, 2026
15D. E. Shaw & Co., Inc.200,756New0.70%$0 MNov 16, 2026
16Accredited Investors Inc.200,000New0.70%$0 MNov 3, 2026
17UBS Group AG189,925-34,308 (-15.30%)0.67%$0 MNov 10, 2026
18Jacobs Levy Equity Management, Inc152,791New0.54%$0 MNov 16, 2026
19Two Sigma Investments, LP131,935-463 (-0.35%)0.46%$0 MNov 16, 2026
20Vanguard Fiduciary Trust Co128,685-270 (-0.21%)0.45%$0 MNov 13, 2026
21Northern Trust Corp127,657+2,890 (+2.32%)0.45%$0 MNov 16, 2026
22AQR Capital Management LLC120,637+15,023 (+14.22%)0.42%$0 MNov 16, 2026
23Cresset Asset Management, LLC116,323+12,474 (+12.01%)0.41%$0 MNov 16, 2026
24Vanguard Portfolio Management LLC107,921+2,006 (+1.89%)0.38%$0 MNov 13, 2026
25Russell Investments Group, Ltd.100,937+96,426 (+2137.57%)0.35%$0 MNov 6, 2026

All 87 institutional investors: 26 to 87, with who bought and sold →

Mutual funds holding CVRx, Inc.#

81 funds hold shares worth $13 M (about 15.2% of the company). Since their previous reports 27 added shares and 21 sold, buying $0 M net.
Mutual funds holding CVRx, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.684,121$4 M4.3%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors371,607$2 M2.3%<0.01%−4.8%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.204,533$1 M1.3%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC165,915$1 M1.0%<0.01%+4.8%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors156,004$1 M0.98%<0.01%+24%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC96,327$1 M0.61%<0.01%+0.8%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.81,934$0 M0.52%<0.01%+3.2%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors51,597$0 M0.33%0.02%+29%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC34,330$0 M0.22%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC36,500$0 M0.23%0.13%−26%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.35,398$0 M0.22%<0.01%+1.3%Jul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC32,926$0 M0.21%0.02%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC27,837$0 M0.18%<0.01%+8.7%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP28,363$0 M0.18%<0.01%−32%Jul 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.27,822$0 M0.18%0.01%+282%Jul 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC27,216$0 M0.17%<0.01%no changeJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC23,044$0 M0.15%<0.01%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC22,120$0 M0.14%<0.01%+44%Jul 31, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.17,997$0 M0.11%0.03%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC15,982$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC16,021$0 M0.10%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP15,865$0 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.14,695$0 M0.09%<0.01%−2.2%May 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.15,059$0 M0.10%<0.01%+70%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC14,568$0 M0.09%<0.01%+19%Jun 30, 2026

As of Jul 31, 2026

Insider trading at CVRx, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$377 K
3 purchases, 2 insiders
Sold, 12 months
$216 K
8 sales, 7 insiders
Net, 12 months
$161 K
open market only
Insiders on file
28
since
$1.1 M-$637 K$0Feb 2024: bought $0 (0 trades), sold $152 K (2 trades)Feb 24Aug 2024: bought $323 K (4 trades), sold $0 (0 trades)AugNov 2024: bought $0 (0 trades), sold $19 K (1 trades)NovMay 2025: bought $1.1 M (7 trades), sold $0 (0 trades)MayNov 2025: bought $0 (0 trades), sold $637 K (6 trades)NovFeb 2026: bought $300 K (2 trades), sold $0 (0 trades)FebMar 2026: bought $0 (0 trades), sold $127 K (5 trades)MarAug 2026: bought $76 K (1 trades), sold $3 K (1 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
CVRx, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John LandryChief Financial OfficerGrant or award+41,433——41,433Form 4
filed Brent BinkowskiCHIEF OPERATING OFFICERBuy+26,223$2.910$76 K56,514Form 4
filed Brent BinkowskiCHIEF OPERATING OFFICERSell10b5-1 plan-1,309$2.550$3 K30,291Form 4
filed Joseph P. SlatteryDirectorGrant or award+8,720——39,365Form 4
filed Michael D. DaleDirectorGrant or award+29,005——29,005Form 4
filed Mitch C. HillDirectorGrant or award+8,720——8,720Form 4
filed Kevin J. BallingerDirectorGrant or award+8,720——8,720Form 4
filed Kirk G. NielsenDirectorGrant or award+8,720——8,720Form 4

Markets and events: CVRx, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.8 M
6.9% of shares · 5.33 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-40 reverse split

Trading halts

  • 2026-11-06 14:36 UTC, code LUDP, resumed 14:41 UTC
  • 2025-05-09 13:30 UTC, code LUDP, resumed 13:35 UTC

Fails to deliver

  • : 2,012 shares at $1.68
  • : 80 shares at $2.63
  • : 513 shares at $2.88
  • : 74 shares at $3.01
  • : 3,885 shares at $3.04

CVRx, Inc. scorecard#

Passes 9 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 9, 2026.

  • Valuation2 of 5
  • Growth4 of 6
  • Profitability1 of 5
  • Financial health2 of 5
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from CVRx, Inc.'s statements, beside the median of Medical Devices.

CVRx, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-90.5%-8.8%
Net margin-94.1%-11.4%
Return on equity-96.6%-18.1%
Revenue growth, 3 years a year36.1%11.7%
Revenue growth10.5%10.5%
Debt to equity1.26×0.60×

3of 9on the Piotroski tests of financial strength

  • Net loss of $53 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$41 million.
  • The share count rose 15.4% in the year.
  • Revenue has grown 5 years in a row.

CVRx, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CVRx, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue57513922136.1
Cost of revenue8.38.36.35.03.61.4
Gross profit484333179.44.6
Research and development11111210.07.56.4
Selling, general and administrative88916550289.7
Operating expenses10010276603516
Operating income−51−59−43−43−26−12
Interest expense and finance costs5.84.41.80.22.22.5
Other non-operating income (expense)3.84.03.91.4−15−0.0
Income before tax−53−60−41−41−43−14
Income tax−0.00.10.10.10.10.1
Net income including minority interests−53−60−41−41−43−14
Net income attributable to shareholders−53−60−41−41−43−14
Earnings per share, basic-2.04-2.65-1.99-2.02-4.16-37.01
Earnings per share, diluted-2.04-2.65-1.99-2.02-4.16-37.01
Shares, weighted average (basic)2623212110—
Shares, weighted average (diluted)26232121100.4
Balance sheet
Cash and cash equivalents761069110614259
Receivables119.37.6r5.52.61.3
Inventory1212117.03.93.3
Other current assets3.12.53.04.22.60.6
Current assets10213011212315164
Property, plant and equipment2.22.51.81.71.40.4
Right-of-use (leased) assets0.91.11.30.30—
Total assets10513311512515365
Accounts payable3.82.61.91.70.50.5
Debt due within a year—————0
Current liabilities13117.98.15.98.0
Long-term debt5049296.7019
Lease liabilities (non-current)0.60.91.20.10—
Total liabilities656239166.628
Retained earnings−591−537−477−436−395−352
Shareholders' equity397176109146−293
Total liabilities and equity10513311512515365
Shares outstanding26252121r200.4
Cash-flow statement
Share-based compensation11196.33.91.90.1
Cash from operating activities−40−39−39−43−28−16
Capital expenditure−0.6−1.4−0.6−0.7−1.2−0.3
Cash from investing activities−0.6−1.4−0.6−0.7−1.2−0.3
Debt repaid———0−210
Shares issued9.033001330
Cash from financing activities1156247.511250
Exchange-rate effect on cash0.0−0.00.0−0.0−0.0−0.0
Change in cash−3015−16−368333
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

What CVRx, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

As of Dec 31, 2025

Where CVRx, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

CVRx, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office$52 M92%
🇩🇪 Germany$5 M8.4%

Events at CVRx, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 7 · Material agreement 2 · New debt 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 15

CVRx, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debtResults announced8-K
Material agreement8-K
Results announced8-K
Directors and officersResults announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
New debt8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Directors and officersResults announced8-K

As of Nov 5, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of CVRx, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$50 MNo. 3$50 to $250 million21equitySEC
May 2016$75 MNo. 2$50 to $250 million20equitySEC
Jun 2013$30 MNo. 1$10 to $50 million12equitySEC

H-1B hiring at CVRx, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $101 K a year.

Certified, FY2026
1
#1,839 among companies on value.today
Worker positions
1
Median wage offered
$101 K
a year, full-time
Applications filed
1
CVRx, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Clinical Research Associate IIClinical Research Coordinators1$101 K

Where: Minneapolis, MN 1

CVRx, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$101 K1
FY202411$70 K1

How CVRx, Inc. compares in Medical Devices

  • Market cap$48 M · higher than 27% of 146
  • Revenue$57 M · higher than 32% of 159
  • Net margin-88.3% · higher than 18% of 148
  • Revenue growth10.4% · higher than 50% of 109
  • Price / sales0.8× · lower than 90% of 99
  • Price / book1.2× · lower than 80% of 103
  • FCF yield-85.2% · higher than 6% of 78

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
CVRx, Inc.🇺🇸$48 M—-88.3%+10.4%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 9, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CVRx, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CVRx, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CVRx, Inc.? Suggest a correction